CYGS Patent Claims Allowed for ssDNA Vector and NCI/NIH Researcher Joins Scientific Advisory Board
Business Wire - January 10, 1999 18:13
HOUSTON--(BUSINESS WIRE)--Jan 10, 1999--Cryogenic Solutions, Inc. (OTC BB:CYGS) announced today that its principal research facility, InGene, Inc., has received notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled Stem-Loop Cloning Vector And Method.
CYGS is the exclusive licensee of this application from InGene. It is anticipated that the patent will issue in the summer of 1999.
This patent application relates to the production and use of single stranded DNA expression vectors which, among other things, can be used in synthesizing sequence specific, antisense competent oligodeoxyribonucleotides in vivo.
Effective delivery of antisense molecules offers a promising method for treatment of a number of diseases and disorders at the most basic genetic level, eliminating the need for drugs or surgery to treat
symptoms or repair the damage caused by faulty, impaired, or inactive genes.
CYGS is currently conducting experiments to demonstrate that their ssDNA expression vector delivers antisense molecules into the cells of living animals, including humans, in sufficient quantities to be
pharmacologically significant.
CYGS also announced the addition to the company*s Scientific Advisory Board of Stephen M. Hewitt, M.D., Ph.D.
Dr. Hewitt was awarded a Ph.D. in Genetics from The University of Texas Health Science Center and the M. D. Anderson Cancer Center in 1995 before earning his M.D. at the University of Texas Health Science Center, Houston Medical School in 1996. He is currently conducting medical research as a resident in Anatomic Pathology in the Laboratory of Pathology, National Cancer Institute, National Institute of Health.
CONTACT: Cryogenic Solutions, Houston
Dell Gibson, 713/780-1399
|
